1. Home
  2. CMCO vs CGEM Comparison

CMCO vs CGEM Comparison

Compare CMCO & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Columbus McKinnon Corporation

CMCO

Columbus McKinnon Corporation

HOLD

Current Price

$15.64

Market Cap

555.6M

Sector

Industrials

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$20.77

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CMCO
CGEM
Founded
1875
2016
Country
United States
United States
Employees
N/A
109
Industry
Construction/Ag Equipment/Trucks
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
555.6M
1.4B
IPO Year
2002
2020

Fundamental Metrics

Financial Performance
Metric
CMCO
CGEM
Price
$15.64
$20.77
Analyst Decision
Buy
Strong Buy
Analyst Count
2
8
Target Price
$21.00
$30.13
AVG Volume (30 Days)
345.2K
750.3K
Earning Date
05-27-2026
05-11-2026
Dividend Yield
1.90%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$936,240,000.00
N/A
Revenue This Year
$19.73
N/A
Revenue Next Year
$82.91
$5.20
P/E Ratio
N/A
N/A
Revenue Growth
3.27
N/A
52 Week Low
$11.99
$5.68
52 Week High
$24.40
$23.19

Technical Indicators

Market Signals
Indicator
CMCO
CGEM
Relative Strength Index (RSI) 36.48 49.46
Support Level $14.62 $11.87
Resistance Level $16.42 $23.19
Average True Range (ATR) 0.73 0.96
MACD -0.31 -0.26
Stochastic Oscillator 4.97 51.40

Price Performance

Historical Comparison
CMCO
CGEM

About CMCO Columbus McKinnon Corporation

Columbus McKinnon Corp is a world-wide designer, manufacturer and marketer of intelligent motion solutions for material handling that move the world forward and improve lives by efficiently and ergonomically moving, lifting, positioning and securing materials. Its key products include hoists, crane components, precision conveyor systems, rigging tools, light rail workstations and digital power and motion control systems. These are relevant, professional-grade solutions that solve its customers critical material handling requirements. The company has one operating and reportable segment. It has presence in United State, Germany, Europe, Middle East, and Africa (Excluding Germany), Canada, Asia Pacific, and Latin America. It has majority of sales from United States.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: